1,022
Participants
Start Date
September 5, 2012
Primary Completion Date
February 28, 2020
Study Completion Date
February 28, 2020
MEDI4736
Participants will receive IV infusion of MEDI4736 for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
Research Site, Leuven
Research Site, Namur
Research Site, Ghent
Research Site, Taipei
Research Site, New York
Research Site, The Bronx
Research Site, Berlin
Research Site, Seongnam-si
Research Site, Pittsburgh
Research Site, Washington D.C.
Research Site, Milan
Research Site, Milan
Research Site, Baltimore
Research Site, Baltimore
Research Site, Fairfax
Research Site, Blacksburg
Research Site, Chapel Hill
Research Site, Huntersville
Research Site, Greenville
Research Site, Athens
Research Site, Augusta
Research Site, Jacksonville
Research Site, Minden
Research Site, Miami Beach
Research Site, Tampa
Research Site, Nashville
Research Site, Columbus
Research Site, Cleveland
Research Site, Ann Arbor
Research Site, Detroit
Research Site, Seogu
Research Site, Siena
Research Site, Minneapolis
Research Site, Saint Louis Park
Research Site, Billings
Research Site, Chicago
Research Site, Gwangju
Research Site, Heidelberg
Research Site, Tainan City
Research Site, Lecce
Research Site, Dallas
Research Site, Paris
Research Site, Houston
Research Site, Houston
Research Site, San Antonio
Research Site, Napoli
Research Site, Gauting
Research Site, Salt Lake City
Research Site, Scottsdale
Research Site, Las Vegas
Research Site, Los Angeles
Research Site, Los Angeles
Research Site, Whittier
Research Site, Burbank
Research Site, Orange
Research Site, San Francisco
Research Site, Villejuif
Research Site, Gilroy
Research Site, Portland
Research Site, Seattle
Research Site, Palo Alto
Research Site, New Haven
Research Site, Boston
Research Site, Hackensack
Research Site, Paterson
Research Site, Philadelphia
Research Site, Liège
Research Site, Ottawa
Research Site, Toronto
Research Site, Montreal
Research Site, Jena
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, London
Research Site, London
Research Site, London
Research Site, Oxford
Research Site, Sutton
Lead Sponsor
MedImmune LLC
INDUSTRY